Form 8-K - Current report:
SEC Accession No. 0001558370-22-013330
Filing Date
2022-08-11
Accepted
2022-08-11 16:46:26
Documents
15
Period of Report
2022-08-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K fbio-20220811x8k.htm   iXBRL 8-K 37413
2 EX-99.1 fbio-20220811xex99d1.htm EX-99.1 416769
3 GRAPHIC fbio-20220811xex99d1001.jpg GRAPHIC 12248
  Complete submission text file 0001558370-22-013330.txt   654050

Data Files

Seq Description Document Type Size
4 EX-101.SCH fbio-20220811.xsd EX-101.SCH 4446
5 EX-101.DEF fbio-20220811_def.xml EX-101.DEF 14245
6 EX-101.LAB fbio-20220811_lab.xml EX-101.LAB 16046
7 EX-101.PRE fbio-20220811_pre.xml EX-101.PRE 13858
9 EXTRACTED XBRL INSTANCE DOCUMENT fbio-20220811x8k_htm.xml XML 7045
Mailing Address 1111 KANE CONCOURSE SUITE 301 BAY HARBOR ISLANDS FL 33154
Business Address 1111 KANE CONCOURSE SUITE 301 BAY HARBOR ISLANDS FL 33154 781-652-4500
Fortress Biotech, Inc. (Filer) CIK: 0001429260 (see all company filings)

EIN.: 205157386 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35366 | Film No.: 221156568
SIC: 2834 Pharmaceutical Preparations